Guidant ACS Multi-Link Duet
This article was originally published in The Gray Sheet
Company files a premarket approval application supplement for rapid exchange and over-the-wire versions of the next-generation coronary stent, Guidant reports May 19. The Duet, an RX version of which was launched in select international markets following receipt of a CE mark Feb. 19 ("The Gray Sheet" March 9, p. 12), offers enhanced radiopacity and deliverability, the firm claims. The PMA supplement seeks approval for the Duet with 8, 13, 18, 23 and 28 mm lengths and 3-4 mm diameters. The wide range of lengths and diameters will allow physicians to treat a broader range of pathologies, Guidant says
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.